New BPCIA Complaint: Amgen Sues Pfizer over Proposed Filgrastim Biosimilar

Today, Amgen filed a complaint for patent infringement under the BPCIA against Hospira and its parent Pfizer concerning their proposed biosimilar of Neupogen® (filgrastim).

According to the complaint, the parties engaged in the patent dance, during which the parties negotiated and ultimately agreed that, of the seven patents that Amgen identified on its list of potentially infringed patents, only the ’997 patent would be the subject of an action for patent infringement under 42 U.S.C. § 262(l)(6).

This case marks the fourth BPCIA litigation concerning a filgrastim biosimilar, following Amgen suits against Sandoz, Apotex and Adello.